{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T23:34:24Z","timestamp":1772667264259,"version":"3.50.1"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.blre.2018.07.004","type":"journal-article","created":{"date-parts":[[2018,7,29]],"date-time":"2018-07-29T07:46:23Z","timestamp":1532850383000},"page":"74-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Current and evolving understanding of atypical chronic myeloid leukemia"],"prefix":"10.1016","volume":"33","author":[{"given":"Lauren C.","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.blre.2018.07.004_bb0005","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2018.07.004_bb0010","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"ADEA. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2008","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.blre.2018.07.004_bb0015","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2018.07.004_bb0020","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/2040620715607416","article-title":"Characteristics and survival of BCR\/ABL negative chronic myeloid leukemia: a retrospective analysis of the surveillance, epidemiology and end results database","volume":"6","author":"Giri","year":"2015","journal-title":"Ther Adv Hematol"},{"issue":"17","key":"10.1016\/j.blre.2018.07.004_bb0025","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2018.07.004_bb0030","first-page":"1566","article-title":"Identification of risk factors in atypical chronic myeloid leukemia","volume":"91","author":"Breccia","year":"2006","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.blre.2018.07.004_bb0035","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1023\/A:1008393002748","article-title":"Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia","volume":"11","author":"Hern\u00e1ndez","year":"2000","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.blre.2018.07.004_bb0040","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1200\/JCO.2001.19.11.2915","article-title":"BCR rearrangement-negative chronic myelogenous leukemia revisited","volume":"19","author":"Kurzrock","year":"2001","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2018.07.004_bb0045","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood.V78.1.205.205","article-title":"Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique","volume":"78","author":"Martiat","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.07.004_bb0050","first-page":"1","article-title":"Atypical chronic myeloid leukaemia: a case of an orphan disease-a multicenter report by the polish adult leukemia group","author":"Drozd-Soko\u0142owska","year":"2018","journal-title":"Hematol Oncol"},{"issue":"2","key":"10.1016\/j.blre.2018.07.004_bb0055","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood.V75.2.445.445","article-title":"Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course","volume":"75","author":"Kurzrock","year":"1990","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2018.07.004_bb0060","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/cncr.10832","article-title":"Characteristics and outcome of patients with Philadelphia chromosome negative, bcr\/abl negative chronic myelogenous leukemia","volume":"95","author":"Onida","year":"2002","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.blre.2018.07.004_bb0065","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0950-3536(87)80031-8","article-title":"Haematological classification of the chronic myeloid leukaemias","volume":"1","author":"Shepherd","year":"1987","journal-title":"Baillieres Clin Haematol"},{"issue":"4","key":"10.1016\/j.blre.2018.07.004_bb0070","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","article-title":"The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British cooperative leukaemia group","volume":"87","author":"Bennett","year":"1994","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2018.07.004_bb0075","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.1995.tb05157.x","article-title":"Philadelphia chromosome-negative chronic myeloid leukaemia: a report of 14 new cases","volume":"90","author":"Costello","year":"1995","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2018.07.004_bb0080","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1046\/j.1365-2141.1996.396933.x","article-title":"Atypical chronic myeloid leukaemia, a distinct clinical entity related to the myelodysplastic syndrome?","volume":"92","author":"Oscier","year":"1996","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.blre.2018.07.004_bb0085","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/0145-2126(96)00028-8","article-title":"Mixed myelodysplastic and myeloproliferative syndromes","volume":"20","author":"Neuwirtov\u00e1","year":"1996","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2018.07.004_bb0090","series-title":"World Health Organization classification of tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues","author":"Jaffe","year":"2001"},{"issue":"10","key":"10.1016\/j.blre.2018.07.004_bb0095","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood-2013-05-500959","article-title":"The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment","volume":"122","author":"Gotlib","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2018.07.004_bb0100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12185-014-1670-3","article-title":"Molecular pathogenesis of atypical CML, CMML and MDS\/MPN-unclassifiable","volume":"101","author":"Zoi","year":"2015","journal-title":"Int J Hematol"},{"issue":"9","key":"10.1016\/j.blre.2018.07.004_bb0105","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/1097-0142(19861101)58:9<2023::AID-CNCR2820580912>3.0.CO;2-H","article-title":"Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia","volume":"58","author":"Kantarjian","year":"1986","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.blre.2018.07.004_bb0110","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2018.07.004_bb0115","first-page":"218","article-title":"Atypical chronic myeloid leukemia with t(9;22)(p24,11.2), a BCR-JAK2 fusion gene","volume":"35","author":"Bellesso","year":"2013","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"10","key":"10.1016\/j.blre.2018.07.004_bb0120","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3109\/10428194.2012.762648","article-title":"A BCR-JAK2 fusion gene from ins(22;9)(q11;p13p24) in a patient with atypical chronic myeloid leukemia","volume":"54","author":"Xu","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.blre.2018.07.004_bb0125","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.2008.07164.x","article-title":"Leukaemia cutis in atypical chronic myeloid leukaemia with a t(9;22) (p24;q11.2) leading to BCR-JAK2 fusion","volume":"142","author":"Lane","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2018.07.004_bb0130","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1111\/j.1751-553X.2011.01351.x","article-title":"Clinical course and molecular features in 21 patients with atypical chronic myeloid leukemia","volume":"34","author":"Koldehoff","year":"2012","journal-title":"Int J Lab Hematol"},{"issue":"12","key":"10.1016\/j.blre.2018.07.004_bb0135","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.leukres.2008.04.024","article-title":"Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm","volume":"32","author":"Fend","year":"2008","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.blre.2018.07.004_bb0140","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","article-title":"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia","volume":"106","author":"Levine","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2018.07.004_bb0145","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","article-title":"JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia","volume":"106","author":"Jelinek","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2018.07.004_bb0150","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1046\/j.1432-1327.2001.02000.x","article-title":"Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET","volume":"268","author":"Minakuchi","year":"2001","journal-title":"Eur J Biochem"},{"issue":"3","key":"10.1016\/j.blre.2018.07.004_bb0155","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2009-06-227363","article-title":"SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia","volume":"115","author":"Blanco","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2018.07.004_bb0160","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40364-017-0113-8","article-title":"SETBP1 mutations as a biomarker for myelodysplasia\/myeloproliferative neoplasm overlap syndrome","volume":"5","author":"Linder","year":"2017","journal-title":"Biomark Res"},{"issue":"1","key":"10.1016\/j.blre.2018.07.004_bb0165","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.blre.2018.07.004_bb0170","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/leu.2013.35","article-title":"SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias","volume":"27","author":"Damm","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.blre.2018.07.004_bb0175","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3324\/haematol.2014.113159","article-title":"Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia","volume":"99","author":"Meggendorfer","year":"2014","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.blre.2018.07.004_bb0180","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2018.07.004_bb0185","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2013.122","article-title":"CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.blre.2018.07.004_bb0190","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00277-015-2366-3","article-title":"De novo CSF3R mutation associated with transformation of myeloproliferative neoplasm to atypical CML","volume":"94","author":"Bartels","year":"2015","journal-title":"Ann Hematol"},{"issue":"25","key":"10.1016\/j.blre.2018.07.004_bb0195","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1182\/blood-2010-01-234120","article-title":"G-CSF and its receptor in myeloid malignancy","volume":"115","author":"Beekman","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2018.07.004_bb0200","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.cyto.2008.03.002","article-title":"Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and \u201cemergency\u201d hematopoiesis","volume":"42","author":"Panopoulos","year":"2008","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.blre.2018.07.004_bb0205","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia","volume":"125","author":"Gambacorti-Passerini","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2018.07.004_bb0210","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/blood-2014-11-609057","article-title":"Mutations of ETNK1 in aCML and CMML","volume":"125","author":"Kosmider","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2018.07.004_bb0215","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ajh.24722","article-title":"Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.blre.2018.07.004_bb0220","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2016-08-693630","article-title":"How I treat atypical chronic myeloid leukemia","volume":"129","author":"Gotlib","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2018.07.004_bb0225","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11899-016-0350-1","article-title":"An exercise in extrapolation: clinical management of atypical CML, MDS\/MPN-unclassifiable, and MDS\/MPN-RS-T","volume":"11","author":"Talati","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"10","key":"10.1016\/j.blre.2018.07.004_bb0230","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bmt.1704472","article-title":"Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative\/BCR-ABL-negative chronic myelogenous leukemia","volume":"33","author":"Mittal","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.blre.2018.07.004_bb0235","doi-asserted-by":"crossref","first-page":"178","DOI":"10.5045\/br.2013.48.3.178","article-title":"Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic\/myeloproliferative neoplasms","volume":"48","author":"Lim","year":"2013","journal-title":"Blood Res"},{"issue":"12","key":"10.1016\/j.blre.2018.07.004_bb0240","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/sj.bmt.1704686","article-title":"Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia","volume":"34","author":"Koldehoff","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.blre.2018.07.004_bb0245","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.14619","article-title":"Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the chronic malignancies working party of the European Society for blood and marrow transplantation","volume":"177","author":"Onida","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2018.07.004_bb0250","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/ejh.12223","article-title":"Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or sanger sequencing predicts clinical relapse in patients with myelodysplastic\/myeloproliferative neoplasms","volume":"92","author":"Fu","year":"2014","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2018.07.004_bb0255","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/bmt.2014.35","article-title":"The CSF3R T618I mutation as a disease-specific marker of atypical CML post allo-SCT","volume":"49","author":"Langabeer","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2018.07.004_bb0260","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF01715120","article-title":"Ph-negative and bcr-negative atypical chronic myelogenous leukemia: biological features and clinical outcome","volume":"65","author":"Montefusco","year":"1992","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.blre.2018.07.004_bb0265","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/cncr.23018","article-title":"PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2018.07.004_bb0270","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/asheducation-2015.1.264","article-title":"What's different about atypical CML and chronic neutrophilic leukemia?","volume":"2015","author":"Dao","year":"2015","journal-title":"Hematology"},{"issue":"2","key":"10.1016\/j.blre.2018.07.004_bb0275","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2217\/fon-2017-0334","article-title":"Atypical chronic myeloid leukemia: a rare entity with management challenges","volume":"14","author":"Dhakal","year":"2018","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.blre.2018.07.004_bb0280","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/ejh.12679","article-title":"Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia","volume":"97","author":"Xicoy","year":"2016","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2018.07.004_bb0285","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1046\/j.1365-2141.1997.4013211.x","article-title":"Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model","volume":"99","author":"Hellstr\u00f6m-Lindberg","year":"1997","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2018.07.004_bb0290","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1046\/j.1365-2141.2003.04153.x","article-title":"A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life","volume":"120","author":"Hellstr\u00f6m-Lindberg","year":"2003","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2018.07.004_bb0295","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/cncr.11543","article-title":"Results of Decitabine (5-Aza-2\u2019Deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.blre.2018.07.004_bb0300","first-page":"2","article-title":"The first case of decitabine successfully in treatment of atypical chronic myeloid leukemia with CEBPA double mutation","volume":"2","author":"Mao","year":"2013","journal-title":"Chemother Open Access"},{"issue":"6","key":"10.1016\/j.blre.2018.07.004_bb0305","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.3109\/10428194.2014.986477","article-title":"Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia","volume":"56","author":"Tong","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.blre.2018.07.004_bb0310","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3892\/ol.2015.3977","article-title":"Decitabine for the treatment of atypical chronic myeloid leukemia: a report of two cases","volume":"11","author":"Jiang","year":"2016","journal-title":"Oncol Lett"},{"issue":"6","key":"10.1016\/j.blre.2018.07.004_bb0315","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/1078155215605662","article-title":"Activity of single-agent decitabine in atypical chronic myeloid leukemia","volume":"22","author":"Hausmann","year":"2016","journal-title":"J Oncol Pharm Pract"},{"issue":"11","key":"10.1016\/j.blre.2018.07.004_bb0320","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/cncr.11416","article-title":"Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders","volume":"97","author":"Cortes","year":"2003","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.blre.2018.07.004_bb0325","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2018.07.004_bb0330","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with Ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2018.07.004_bb0335","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia Vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.blre.2018.07.004_bb0340","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood-2013-06-509976","article-title":"The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition","volume":"122","author":"Fleischman","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2018.07.004_bb0345","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/1078-0432.CCR-14-3100","article-title":"The Colony-stimulating factor 3 receptor T640N mutation is oncogenic, sensitive to JAK inhibition, and mimics T618I","volume":"22","author":"Maxson","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.blre.2018.07.004_bb0350","first-page":"67","article-title":"Significant clinical response to JAK1\/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia","volume":"3","author":"Dao","year":"2015","journal-title":"Leuk Res Rep"},{"issue":"1","key":"10.1016\/j.blre.2018.07.004_bb0355","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/pbc.25694","article-title":"Atypical chronic myeloid leukemia in two pediatric patients","volume":"63","author":"Freedman","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2018.07.004_bb0360","first-page":"1","article-title":"A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms","volume":"00","author":"Assi","year":"2017","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.blre.2018.07.004_bb0365","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00277-014-2272-0","article-title":"Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib","volume":"94","author":"Ammatuna","year":"2015","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.blre.2018.07.004_bb0370","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00277-016-2664-4","article-title":"Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia","volume":"95","author":"Stahl","year":"2016","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.blre.2018.07.004_bb0375","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1\/2 inhibitors","volume":"22","author":"Shanavas","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.blre.2018.07.004_bb0380","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1158\/1535-7163.MCT-11-0505","article-title":"Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212","volume":"11","author":"Jing","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"26","key":"10.1016\/j.blre.2018.07.004_bb0385","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1182\/blood-2014-05-574582","article-title":"Preclinical efficacy of MEK inhibition in Nras-mutant AML","volume":"124","author":"Burgess","year":"2014","journal-title":"Blood"},{"issue":"59","key":"10.1016\/j.blre.2018.07.004_bb0390","doi-asserted-by":"crossref","first-page":"99215","DOI":"10.18632\/oncotarget.22283","article-title":"MEK\/ERK addiction in CNL\/aCML","volume":"8","author":"Kesarwani","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.blre.2018.07.004_bb0395","article-title":"Durable disease control with MEK inhibition in a patient with NRAS-mutated atypical chronic myeloid leukemia","volume":"7","author":"Khanna","year":"2015","journal-title":"Cur\u0113us"},{"issue":"12","key":"10.1016\/j.blre.2018.07.004_bb0400","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/cncr.29986","article-title":"Activity of the oral MEK inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies","volume":"122","author":"Borthakur","year":"2016","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.blre.2018.07.004_bb0405","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2018.07.004_bb0410","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.blre.2018.07.004_bb0415","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2010.294","article-title":"PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect","volume":"25","author":"Cristobal","year":"2011","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.blre.2018.07.004_bb0420","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2018.07.004_bb0425","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.hoc.2017.04.004","article-title":"Kinase inhibitor screening in myeloid malignancies","volume":"31","author":"Tyner","year":"2017","journal-title":"Hematol Oncol Clin North Am"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X1830064X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X1830064X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T08:27:07Z","timestamp":1571646427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X1830064X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":85,"alternative-id":["S0268960X1830064X"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2018.07.004","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and evolving understanding of atypical chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2018.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}